Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26383818 | 0.95 | EGFR (0.46) | EGFRLRRK2JAK2TTKALK | |
| SCHEMBL26384130 | 0.91 | EGFR (0.51) | EGFRLRRK2JAK2ALK | |
| SCHEMBL26395904 | 0.90 | LRRK2 (0.56) | EGFRLRRK2JAK2TTKALK | |
| SCHEMBL26397089 | 0.88 | EGFR (0.47) | EGFRJAK2TTKALK | |
| SCHEMBL26397329 | 0.86 | NTRK1 (0.48) | EGFRJAK2 | |
| SCHEMBL26383829 | 0.84 | LRRK2 (0.59) | EGFRLRRK2JAK2 | |
| SCHEMBL26401974 | 0.84 | EGFR (0.56) | EGFRLRRK2 | |
| SCHEMBL26384116 | 0.83 | IGF1R (0.56) | EGFRJAK2ALK | |
| SCHEMBL26397273 | 0.83 | EGFR (0.57) | EGFRALK | |
| SCHEMBL26384215 | 0.82 | EGFR (0.47) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885LRRK2 624/4885JAK2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.